Cargando…
Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment
SIMPLE SUMMARY: Our research team has identified the cholecystokinin-B receptor (or CCK-BR) as a novel target for treatment of pancreatic cancer. CCK-BRs are over-expressed in pancreatic cancer and activation stimulates growth in cell culture and in animal models. CCK-BRs are also expressed on pancr...
Autores principales: | Malchiodi, Zoe X., Cao, Hong, Gay, Martha D., Safronenka, Anita, Bansal, Sunil, Tucker, Robin D., Weinberg, Benjamin A., Cheema, Amrita, Shivapurkar, Narayan, Smith, Jill P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508339/ https://www.ncbi.nlm.nih.gov/pubmed/34638432 http://dx.doi.org/10.3390/cancers13194949 |
Ejemplares similares
-
4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines
por: Gay, Martha, et al.
Publicado: (2020) -
25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma
por: Gay, Martha Dee, et al.
Publicado: (2021) -
Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic
por: Jolly, Gurbani, et al.
Publicado: (2023) -
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019) -
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022)